Longboard pharmaceuticals to report second quarter 2024 financial results and host corporate update call on august 1

La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release second quarter 2024 financial results and provide a corporate update, including topline phase 1 sad data for lp659, its centrally acting, highly selective sphingosine-1-phosphate (s1p) receptor modulator, on august 1, 2024. the company will host a con.
LBPH Ratings Summary
LBPH Quant Ranking